BPH Energy Limited Overview
BPH Energy Limited is a Perth-based, ASX-listed investment holding company. It raises equity from public markets and deploys it, mainly through loans and minority equity stakes, into a small portfolio of unlisted Australian and international ventures. These span upstream gas exploration, clean-hydrogen technology and medical devices.
Its economic value is dominated by one asset: a 35.8% stake in, and a large loan book to, Advent Energy Limited. Advent's subsidiary Asset Energy holds 85% of Petroleum Exploration Permit PEP-11 in the offshore Sydney Basin. PEP-11 carries a P50 prospective resource of 5.7 Tcf gross, of which Advent's net share is 4.9 Tcf. The permit's extension was refused by the Commonwealth–NSW Joint Authority, a refusal upheld by the Federal Court in June 2026 and now under appeal.
Secondary holdings are:
-
Cortical Dynamics (16.3%): developer of the BARM 2.0 AI-enabled brain and pain monitor.
-
Clean Hydrogen Technologies Corporation (16.1%): methane pyrolysis producing turquoise hydrogen and carbon nanotubes.
-
Molecular Discovery Systems (20%): liver-cancer gene research.
The company is effectively a leveraged legal and regulatory option on PEP-11, alongside venture-stage biotech and hydrogen exposures. It trades at a deep discount to book value.
Company's own description (FY26 AR, Review of Operations)
The FY26 AR describes BPH as a company that uses funds raised to provide financial support to, and make direct investments in, a number of investees, associates and related companies. These include Advent Energy Limited, Cortical Dynamics Limited, MEC Resources Limited and Clean Hydrogen Technologies Corporation.
The Directors' Report defines principal activities as "investments in biotechnology and oil and gas exploration entities". Under future developments, the company says it will continue investing in energy resources and helping investees commercialise biomedical research developed in universities, medical institutes and hospitals.
Independent characterisation
BPH is best described as a listed closed-end venture vehicle with three features:
-
Concentrated related-party financing. BPH's main use of cash is lending to Advent Energy, a company whose board includes BPH's chairman, David Breeze.
-
Loans advanced were A$3.68m in FY25 and A$3.66m in FY26.
-
Over FY22–FY26, about A$15.7m was advanced in total, against about A$4.9m repaid (FY22, FY25 and FY26 cash flow statements; FY23–FY24 loan detail not separately verified).
-
Interest accrues on these loans and forms most of BPH's reported "finance income".
-
-
Fair-value-driven earnings. Reported profits in FY24 and FY25 came from fair-value gains on unlisted holdings (A$6.93m in FY25) and equity-accounted results, not from cash revenues. The FY26 loss was driven by a A$7.02m expected credit loss provision and a swing in associate results.
-
Equity-funded overhead. The company has no operating cash inflows apart from interest receipts (A$127k in FY26). Corporate overhead and investee funding are met by recurring share and option issues.
Revenue model
| Revenue type | Share of FY26 "finance income" | Comment |
|---|---|---|
| Product sales | 0% | — |
| Services | 0% | None. An earlier biomedical-services description in aggregator profiles is not reflected in current filings |
| Subscription / licensing | 0% | None at the BPH level |
| Interest income on loans to investees and on cash | 100% of A$1,042,417 | Mostly accrued (non-cash) interest. Only A$127,279 of interest was received in cash in FY26 |
Value-chain position, customers and end-markets
| End-market | Exposure route |
|---|---|
| East-coast Australian natural gas | Via Advent / PEP-11 |
| Northern Australia onshore gas | Via Advent's Onshore Energy subsidiary, now under a Deed of Company Arrangement |
| Low-carbon hydrogen and battery-grade conductive carbon (India, USA, Singapore) | Via Clean Hydrogen Technologies |
| Anaesthesia and critical-care brain monitoring (global medtech) | Via Cortical Dynamics |
| Oncology diagnostics and therapeutics research | Via Molecular Discovery Systems |
BPH sits at the capital-provision end of the value chain. It has no customers in the conventional sense. Its "counterparties" are its investees. The end-markets it is exposed to indirectly are:
Strategy
Stated strategy themes (FY26 AR)
-
Continue investment in energy resources.
-
Help investee companies commercialise "breakthrough biomedical research" from universities, medical institutes and hospitals.
-
Through Advent, support NSW energy security with gas located closest to Australia's largest domestic market. Gas is positioned as firming support for renewables, with optional carbon capture and storage exploration offshore NSW, aligned with Net Zero 2050.
Initiatives in the last 24 months
| Date | Initiative | Detail |
|---|---|---|
| Aug 2024 → Jul 2026 | PEP-11 litigation programme | Three judicial and appellate actions (Aug 2024 mandamus; Feb 2025 review; Jul 2026 appeal), plus a Mar 2025 renewal application over 50% of the area |
| Mid-2024 → 2026 | CHT commercialisation | Indian production facility design; ASME and IS2825 certification; Horizon Fuel Cells LOI; Singapore electricity generation company letter of support; planned NASDAQ SPAC listing |
| 1 Jan 2026 | CHT option reset | New 5-year options at US$3,000 replace exercised seed options; 760 outstanding |
| FY25–FY26 | Cortical US strategy | US advisory team formed: Lt Gen Roger Cloutier (Ret) and Brig Gen Shan Bagby (Ret). Detroit investor presentations; Henry Ford Health engagement; Mayo Clinic presentation (Mar 2026) |
| FY26 | BARM 2.0 and CORDYAN™ | MVP completion, safety testing, then US and Netherlands trials |
| Oct 2025 → Feb 2026 | Option reloading | 622m expired 3c options replaced by new 3c options (542.9m issued at A$0.001, plus 10.7m to directors). Placement attaching and broker options lift the Feb 2027 series to 710.7m |
| Jan 2026 | A$1.208m placement | Use of funds: A$0.85m oil and gas, A$0.25m Cortical, A$0.1m working capital |
| Apr–Jul 2026 | Onshore Energy restructuring | Voluntary administration, then Deed of Company Arrangement |
Cost programmes: no formal programme or target disclosed. Administration costs fell 25% in FY26.
ESG commitments: none at the BPH level beyond Advent's stated Net Zero 2050 support.
Medium-term financial targets or guidance: none disclosed.
Products & Services
BPH sells no products. Its "portfolio" is the asset and technology set of its investees, catalogued below.
Energy: Advent Energy (BPH 35.8%)
PEP-11, offshore Sydney Basin (Asset Energy 85%, Bounty Oil & Gas NL 15%)
Area and location: about 4,649 km², offshore the lower Hunter region, NSW. Prospects lie generally less than 50 km from the Sydney–Wollongong–Newcastle metropolitan area and gas pipeline network. It is the only petroleum title offshore NSW.
Resource: total P50 prospective resource of 5.7 Tcf, with 4.9 Tcf net to Advent (FY26 AR). This compares with 5.9 Tcf gross and 5.0 Tcf net in the FY22 4E, a downward revision not explained in the reviewed documents. Flagship prospects are Fish and Baleen. Baleen was ranked highest probability of success by the 2010 geochemical study.
Technical basis: - 2004 2D seismic data reprocessed in 2010, showing hydrocarbon-related diagenetic zones, amplitude-versus-offset anomalies and potential flat spots.
- One well, New Seaclem-1 (2010).
Status: extension and variation applications refused (17 Jan 2025). Judicial review dismissed (17 Jun 2026). Appeal to the Full Court lodged (13 Jul 2026). A separate renewal application over 50% of the area is pending with NOPTA (lodged Mar 2025).
Carrying value at risk: Asset Energy carries capitalised exploration and evaluation expenditure of A$16.8m. This must be written off if tenure is lost (FY26 AR risk section).
Stated secondary use: carbon capture and storage exploration offshore NSW. Advent states support for Net Zero by 2050.
EP386 and RL1, onshore Bonaparte Basin (Onshore Energy 100%)
-
RL1 covers 166 km² over the Weaber Gas Field, discovered in 1985. RISC-audited contingent resources are 11.5 Bcf (2C) and 45.8 Bcf (3C) (FY22 4E).
-
A market study cited up to 30.8 TJ/day of potential Kimberley power-generation demand.
Status: Onshore Energy entered voluntary administration on 10 Apr 2026 (administrator Bryan Hughes, 101 Advisory). A Deed of Company Arrangement was approved on 24 Jul 2026, and a proposal was sent to the WA Department of Mines (DMPE).
Taranaki Basin farm-in (Aotearoa Offshore Ltd)
-
Right to a 30% interest in PEP 57075, 60092 and 60093 (5,180 km²) from OMV NZ under a farm-out agreement signed 24 Dec 2021.
-
BPH lent Advent A$3.0m for related payments in 2022.
-
Current status is not publicly disclosed in the FY26 AR.
Clean energy technology: Clean Hydrogen Technologies Corp (BPH 16.1%)
| Attribute | Detail (FY26 AR) |
|---|---|
| Core process | Methane pyrolysis using a patented catalyst in a modified fluidised-bed reactor. Average cracking efficiency of 92% at proof-of-concept scale. No CO₂ emitted in the core process and no water used |
| Products | Turquoise hydrogen, and a carbon composite that is mostly carbon nanotubes (CNT) and carbon nanofibres. The CNT composite represents most of CHT's projected revenue |
| Pilot plant | Nashik, India. Consistent two-product output demonstrated from mid-2024 |
| First commercial plant design | Maharashtra, India. Stage 1 capacity of 820 t/yr hydrogen and 2,462 t/yr carbon composite. Louisiana, USA is a likely second site |
| Engineering certification | ASME (USA) and IS2825 (India) design reviews "almost complete" |
| Commercial pipeline | MOU-stage discussions on CNT use in grid-scale batteries and cement. Letter of support from a Singapore electricity generation company (Jurong Island low-carbon data centres). Letter of Intent with Horizon Fuel Cells for hydrogen supply to US data-centre fuel cells |
| Corporate plan | Capital raise at US$3,000 per share for up to US$2.5m, expected by Nov 2026. Intended NASDAQ listing via a special-purpose acquisition company (SPAC) |
| BPH options | 760 options outstanding at US$3,000, with 5-year expiry from replacement on 1 Jan 2026. 139 original options exercised |
| Pricing model | — |
Medical technology: Cortical Dynamics Ltd (BPH 16.3%)
| Product | Description | Status |
|---|---|---|
| BARM™ (first generation) | EEG-based brain anaesthetic response monitor whose index is grounded in brain physiology. Focus on total intravenous anaesthesia (TIVA) | TGA approval, Korean MFDS approval and CE mark obtained. FDA 510(k) process started in 2022 with advisers MCRA (FY22 4E). Patent position (2022): 5 families, 36 granted patents |
| BARM 2.0 | Next-generation AI-enhanced monitor that, per the company, is the only system unifying hypnotic depth and pain-response monitoring in one EEG plus AI platform | Minimum viable product "nearing completion". Then electromagnetic compatibility and electrical safety testing. Clinical trials planned in the USA and the Netherlands, followed by worldwide regulatory submissions |
| BarSensors™ | Proprietary new EEG sensors for BARM 2.0 | Biocompatibility and ageing (shelf-life) testing pending |
| CORDYAN™ | AI and deep-learning predictive medical apps, usable standalone, with BARM 2.0, or integrated into hospital systems and electronic medical records | In development, supported by matched grants from MTPConnect and ARM Hub |
Target customers: anaesthetists, hospitals and health systems; later ICU, neurodiagnostics and drug evaluation.
Pricing: not publicly disclosed.
Biotechnology: Molecular Discovery Systems Ltd (BPH 20%)
-
Validates HLS5 (TRIM35) as a tumour-suppressor gene in liver cancer (hepatocellular carcinoma) with the Harry Perkins Institute of Medical Research.
-
Supporting literature from Fudan University and other Chinese institutes describes an HLS5–PKM2 binding mechanism and a prognostic study of 688 patients.
-
No product, revenue or trial programme is disclosed.
-
BPH's investment is fully impaired. The gross loan receivable was A$1.54m at FY22, fully provided.
Financial Narrative
Basis: consolidated AASB/IFRS accounts. FY22, FY25 and FY26 come from primary filings. FY23 and FY24 income figures come from the FY26 AR five-year table. FY23 and FY24 balance sheet and cash flow figures come from aggregator data (InvestSMART, Stockopedia, Kalkine) and should be treated as approximate.
Income statement
How these figures were built:
-
Corporate overheads are the sum of administration and promotion, consulting and legal, directors' fees, service expenses and share-based payments. FY26: 417.2 + 225.4 + 100.0 + 128.6 + 481.5 = A$1,352.8k.
-
FY22 other income of A$68.1k (sub-underwriting fees) is included in the FY22 core result.
-
Gross profit is not applicable, as the company has no cost of sales.
-
EBITDA is approximately equal to pre-tax income: there is no depreciation or amortisation, interest expense was A$11 in FY26 and A$105 in FY22, and tax is nil in all years.
FY22, FY25 and FY26 ratios are company-reported (Appendix 4E). FY23 and FY24 are derived from the five-year table. Margins are not economically meaningful for an investment vehicle and are shown for completeness only.
Revenue CAGR FY22–FY26: about 61% per year (A$154.7k to A$1,042.4k). This growth is almost entirely accrued interest on the rising Advent loan book, not commercial revenue.
Commentary.
FY26 was the inflection year: BPH booked a A$7.02m expected credit loss, a A$2.22m share of associate losses (Advent, after the PEP-11 judgment and the Onshore Energy administration) and a A$0.64m fair-value loss. The 1H FY26 report attributes part of the fair-value loss to exchange-rate movements on the US$-denominated CHT holding.
Inferred attribution: The scale and timing of the credit-loss charge indicate it relates predominantly to Advent loan receivables after the 17 Jun 2026 judgment.
Cost discipline is visible: Administration and promotion fell 25% YoY (A$560k to A$417k), and the core cash-overhead line improved.
Balance sheet
Notes:
-
FY23 total assets, cash, current assets, liabilities and equity are aggregator-rounded (InvestSMART and Stockopedia).
-
FY24 cash, equity, issued capital and accumulated losses are taken from the FY26 AR statement of changes in equity and the FY25 cash flow opening balance. FY24 total assets and current assets are aggregator figures (Kalkine A$30.29m).
Commentary.
-
The balance sheet is almost entirely illiquid unlisted assets: about A$26.2m of A$31.2m (84%) at FY26 is non-current.
-
Cash has fallen in three consecutive years, from A$6.42m (FY24) to A$2.28m (FY26).
-
The group is debt-free apart from a A$65k interest-free borrowing.
-
A further A$625k of directors' fees has been accrued but not paid and sits within payables (A$521k at FY25). In effect, directors are financing the company.
Cash flow
Notes:
-
FY23 operating, investing and financing flows are from Stockopedia and Kalkine.
-
FY24 operating cash flow of −A$0.94m is from InvestSMART. FY24 investing (about −A$3m) and financing (about +A$5m) are reported only in rounded form by InvestSMART and are left blank here.
-
The FY26 loan repayment of A$876.6k was by Cortical Dynamics, on 5 Feb 2026, from its R&D tax incentive refund.
Commentary.
-
Operating burn has fallen each year since FY23, down 44% from FY23 to FY26.
-
The real cash drain is investing outflow, driven by recurring loans to Advent (about A$3.7m per year in FY25 and FY26).
-
The Jun-26 Appendix 4C reported 38.7 quarters of funding available. That metric covers operating outflows only and excludes discretionary investee lending, so it materially overstates the effective runway if Advent funding continues at FY26 rates.
-
At FY26 run-rates (about A$0.6m operating plus about A$2.8m net investing per year), the A$2.28m cash balance implies a need for new equity or a sharp reduction in Advent lending within FY27. This is an analyst inference.
Ratios
Notes:
- FY22, FY25 and FY26 ROE are company-reported. Other ratios are analyst-derived from the tables above; FY23 and FY24 use aggregator balances.
ROIC: not meaningful (equity-funded, no operating invested capital).
Net debt / EBITDA: not meaningful (net cash, and EBITDA swings sign).
Interest coverage: not meaningful (interest expense of A$11 in FY26).
Asset turnover: about 0.03x in FY26 (finance income / total assets).
Cash conversion cycle: not applicable.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | BPH interest | Accounting treatment | Activity | Domicile |
|---|---|---|---|---|
Advent Energy Ltd | 35.8% direct (35.81% per Jul 2026 announcements) | Associate (equity method), plus loans at amortised cost | Oil and gas exploration | Australia (unlisted) |
Asset Energy Pty Ltd | 100% of Advent | Held via Advent | 85% of PEP-11 and JV operator | Australia |
Onshore Energy Pty Ltd | 100% of Advent | Held via Advent; under Deed of Company Arrangement | EP386 and RL1 (Bonaparte Basin) | Australia |
Aotearoa Offshore Ltd (NZ) | 100% of Advent | Held via Advent | Taranaki farm-in vehicle (current status not disclosed) | New Zealand |
Cortical Dynamics Ltd | 16.3% (FY26 AR); 16.4% (Jun-26 quarterly); 17.7% (FY22) | Financial asset at fair value through profit or loss | Medical devices | Australia (unlisted) |
Clean Hydrogen Technologies Corp | 16.1%, plus 760 options at US$3,000 | Financial asset at fair value through profit or loss | Hydrogen and carbon nanotubes | USA (unlisted) |
Molecular Discovery Systems Ltd | 20% | Associate, fully impaired | Cancer research | Australia (unlisted) |
MEC Resources Ltd | Small listed shareholding plus secured loan (FY22) | Financial asset | Investment company | Australia (ASX-listed) |
Controlled subsidiaries | — | Consolidated. Non-controlling interest was −A$165k at FY26 | Not publicly disclosed in reviewed extracts | Australia |
Revenue by Segment and Segment Assets & Liabilities
| Category (AUD K) | FY2022 | FY2025 | FY2026 |
|---|---|---|---|
Investments in associates (Advent and MDS) | 3,942 | 4,226 | 2,029 |
Non-current financial assets (loans and FVTPL equity) | 8,193 | 24,210 | 24,153 |
Current financial assets | 123 | 6,567 | 2,676 |
Cash and equivalents | 2,895 | 4,066 | 2,281 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Finance income / revenue (AUD K) | 154.7 | 304.1 | 843.7 | 836.6 | 1,042.4 |
Revenue growth YoY (%) | 136.2 | 96.6 | 177.5 | -0.8 | 24.6 |
Fair value gain/(loss) (AUD K) | 0 | — | — | 6,930.2 | -639.9 |
Share of associates' profit/(loss) (AUD K) | -405.5 | — | — | 672.5 | -2,223.3 |
Expected credit losses (AUD K) | -88.4 | — | — | -110.4 | -7,016.3 |
Corporate overheads incl. share-based payments (AUD K) | -824.4 | — | — | -1,565.0 | -1,352.8 |
Core result: finance income + other income − overheads (AUD K) | -601.6 | — | — | -728.4 | -310.4 |
EBITDA (AUD K) | -1,078.5 | — | — | 6,785.9 | -10,163.3 |
Pre-tax income (AUD K) | -1,078.6 | 852.3 | 4,555.4 | 6,785.9 | -10,163.3 |
Net income (AUD K) | -1,078.6 | 852.3 | 4,555.4 | 6,785.9 | -10,163.3 |
EPS basic (A$ cents) | -0.16 | 0.10 | 0.44 | 0.56 | -0.79 |
EPS diluted (A$ cents) | -0.16 | — | — | 0.54 | -0.79 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin metric
| Margin metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Pre-tax income / revenue (%) | -697 | 280 | 540 | 811 | -975 |
Net margin (%) | -697 | 280 | 540 | 811 | -975 |
Balance Sheet
| Metric (AUD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets | 15,208.6 | 20,400 | 30,290 | 39,183.1 | 31,231.3 |
Cash and equivalents | 2,895.0 | 5,610 | 6,423.0 | 4,066.3 | 2,281.0 |
Total current assets | 3,053.9 | 7,000 | 10,320 | 10,747.2 | 5,049.1 |
Non-current financial assets | 8,193.0 | — | — | 24,210.0 | 24,153.0 |
Investments in associates | 3,941.7 | — | — | 4,225.9 | 2,029.2 |
Total liabilities | 908.8 | 985 | 985 | 697.2 | 801.1 |
Short-term debt (unsecured, interest-free borrowings) | 104.8 | — | — | 84.8 | 65.0 |
Long-term debt | 0 | 0 | 0 | 0 | 0 |
Net debt (negative = net cash) | -2,790.2 | — | — | -3,981.5 | -2,216.0 |
Total equity | 14,299.8 | 19,400 | 29,300.4 | 38,485.9 | 30,430.3 |
Goodwill and intangibles | 0 | 0 | 0 | 0 | 0 |
Working capital | 2,145.2 | — | — | 10,050.0 | 4,248.0 |
Issued capital | 58,844.6 | — | 66,360.5 | 67,563.0 | 68,592.4 |
Accumulated losses | -45,489.4 | — | -40,079.0 | -33,292.1 | -43,455.1 |
Cash Flow
| Metric (AUD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow | -1,022.1 | -1,050.6 | -940 | -736.9 | -587.5 |
Capex | 0 | 0 | 0 | 0 | 0 |
Free cash flow (operating cash flow − capex) | -1,022.1 | -1,050.6 | -940 | -736.9 | -587.5 |
Investing cash flow | -6,257.6 | -217 | — | -3,122.6 | -2,778.5 |
Loans advanced to investees | -4,740.8 | — | — | -3,683.1 | -3,655.1 |
Loans repaid by investees | 1,124.7 | — | — | 987.7 | 876.6 |
Financing cash flow | 1.4 | 3,990 | — | 1,502.8 | 1,580.7 |
Net equity proceeds | 1.4 | — | — | 1,502.8 | 1,600.5 |
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Buybacks | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (% of closing equity) | -7.5 | 4.4 | 15.5 | 17.6 | -33.4 |
ROA (% of closing total assets) | -7.1 | 4.2 | 15.0 | 17.3 | -32.5 |
Current ratio (x) | 3.36 | 7.11 | 10.48 | 15.41 | 6.30 |
Debt / equity (%) | 0.7 | — | — | 0.2 | 0.2 |
Results by Region
| Region (AUD K) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia (finance income) | 843.7 | 836.6 | 1,042.4 |
Rest of world | 0 | 0 | 0 |
Region Overview
| Region | Exposure |
|---|---|
Australia | NSW (PEP-11), WA/NT (Bonaparte, now under DOCA), and Cortical and MDS in Victoria and WA |
United States | CHT incorporation and its planned Louisiana site; Cortical's US commercial focus |
India | CHT pilot plant in Nashik and the Stage 1 plant in Maharashtra |
Singapore | CHT hydrogen opportunity |
Netherlands | Planned BARM 2.0 trial site |
New Zealand | Advent's Taranaki interest (status not disclosed) |
Per-Share Data and Share Count (millions)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at 30 June (A$ cents) | 1.1 | 2.3 | 1.9 | 0.8 | 0.3 |
Shares on issue at year-end (millions) | 664.9 | — | — | — | 1,350 |
Return period to 30 Jun 2026
| Return period to 30 Jun 2026 | Total return |
|---|---|
1 year | −62.5% (0.8c → 0.3c) |
3 years | −87.0% (2.3c → 0.3c) |
5 years | From FY22 (1.1c) the decline is −72.7% |
Valuation Multiples
| Multiple | BPH | Comment |
|---|---|---|
P/E | Not meaningful (FY26 loss) | Google Finance showed 1.49x on trailing FY25 profit earlier in 2026 |
P/B | about 0.13x | Market capitalisation about A$4.0m vs equity of A$30.4m |
Price / NTA | about 0.14x | 0.3c vs 2.2c NTA per share |
EV / Sales | about 1.7x | EV about A$1.8m (market capitalisation minus net cash of A$2.2m) vs A$1.04m finance income |
Capital Markets
| Item | Position |
|---|---|
Analyst consensus | None (no coverage; StockAnalysis shows n/a) |
Dividends | Nil in every year; no dividend policy |
Buybacks | None authorised |
Credit ratings | None (Moody's, S&P, Fitch: not rated) |
Debt maturity profile | Only A$65k current, unsecured, interest-free borrowings |
Next scheduled reports | Interim 16 Feb 2027; preliminary final 30 Aug 2027 (InvestSMART calendar). September quarter 4C due by 31 Oct 2026 |
Series Details
| Series | Number | Exercise price (AUD) | Expiry |
|---|---|---|---|
December 2025 (directors) | 10,664,440 | 0.03 | 27 Dec 2026 |
February 2026 (prospectus, placement and broker) | 710,668,268 | 0.03 | 10 Feb 2027 |
November 2025 (Breeze) | 5,000,000 | 0.03 | 30 Nov 2026 |
November 2023 | 5,250,000 | 0.05 | 7 Dec 2028 |
Performance rights (Breeze) | 58,000,000 | 0 | 30 Nov 2028 |
Analyst Conclusions
Management guidance and consensus
Management provides no financial guidance. The only forward statements are:
-
continued investment in energy and biomedical commercialisation;
-
the PEP-11 appeal, whose timing is "a matter for the Full Court";
-
CHT's capital raise by Nov 2026 and intended NASDAQ SPAC;
-
BARM 2.0 technical completion followed by trials in the USA and the Netherlands.
No analyst consensus exists.
Bull case
-
Binary asymmetry on PEP-11. Market capitalisation of about A$4m against a 4.9 Tcf net prospective resource. The court accepted that procedural fairness was denied, giving appeal arguments substance, and a separate NOPTA renewal application over 50% of the area remains live.
-
CHT liquidity event. A completed US$2.5m raise at US$3,000 per share and a SPAC listing would provide an external mark for BPH's 16.1% stake plus 760 options, which are valued on the balance sheet but unrealisable today.
-
Deep discount to assets. Price is about 0.14x NTA, with debt-free status and a falling overhead base (A$0.59m operating burn in FY26). Even after the A$7m credit-loss reset, book equity is about 7.5 times market capitalisation.
Bear case
-
The public-interest ground is near-dispositive. The court held refusal was independently justified on public-interest grounds, so overturning it on appeal is difficult. Loss of tenure removes A$16.8m of Advent's capitalised exploration and leaves BPH's remaining Advent exposure (A$2.0m associate carrying value plus residual loans) exposed to further impairment.
-
Cash and dilution spiral. Cash is A$2.28m with about A$3.4m per year of outflows at FY26 rates. The share price is at 0.2–0.3c, there are over 726m out-of-the-money options, and Advent itself discloses insufficient working capital.
-
Governance and related-party structure. Capital flows from public shareholders to unlisted entities overseen by the same chairman. There is one formal board meeting a year, no D&O insurance and accrued unpaid director fees. Valuation marks on unlisted holdings are not market-tested.
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| By 31 Oct 2026 | September quarter Appendix 4C: cash balance and Advent loan advances |
| Nov 2026 (expected) | AGM: remuneration vote, capital authority, director re-elections |
| By Nov 2026 | CHT US$2.5m capital raise completion; SPAC counterparty announcement |
| Nov–Dec 2026 | Expiry of 5m (30 Nov) and 10.7m (27 Dec) 3c options |
| Not set | Full Court listing and hearing date for the PEP-11 appeal |
| Not set | NOPTA decision on the PEP-11 renewal application (50% area) |
| Ongoing | Onshore Energy DOCA implementation and DMPE response |
| Ongoing | BARM 2.0 MVP completion, safety testing and first trial enrolment |
| 10 Feb 2027 | Expiry of 710.7m 3c options |
| 16 Feb 2027 | 1H FY27 results: further credit losses or fair-value movements |
| Any time | New equity raise: size, price and dilution |
Analyst verdict
BPH Energy is not an operating business. It is a thinly governed capital conduit whose value rests almost entirely on the outcome of one contested regulatory and legal question: whether PEP-11 survives. FY2026 marked the point at which accounting caught up with that reality.
The A$7.0m expected credit loss and A$2.2m associate loss cut net assets by over a fifth, to A$30.4m. The 17 June 2026 Federal Court judgment removed the principal near-term route to reinstating the permit. The court's finding that the public-interest ground independently justified refusal is the most important sentence in the judgment, because it narrows the appeal's prospects even where procedural unfairness was established.
Against this, the market already prices BPH at roughly one-seventh of book value. At about A$4m market capitalisation, it is valuing the PEP-11 option, the CHT stake and options, Cortical and MDS at little or nothing. That is the essence of the bull case: any positive surprise would be large relative to the equity value. Possible surprises include a successful appeal, a NOPTA renewal over half the permit area, or a CHT liquidity event at the indicated US$3,000 per share.
The structural problems are, however, real and persistent:
Funding: Cash covers well under a year of operating plus investee-lending outflows at FY26 rates.
Capital raising: Further equity must be raised near 0.2–0.3c, against a share register that has already doubled since 2020.
Valuation and control: Unlisted holdings are marked without market tests. Capital deployment decisions concentrate in a single executive who also sits on the boards of the borrowers.
Overall assessment: a high-risk, binary special situation suitable only for speculative capital with a view on the PEP-11 appeal or on CHT's listing pathway. The base case for the next 12 months is further dilution and continued book-value erosion, absent a favourable Full Court or NOPTA outcome. Monitor the September quarter cash balance, the CHT raise and the appeal timetable as the decisive near-term signals.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure | Age (FY26 AR) | Background | Other directorships |
|---|---|---|---|---|---|
David Breeze | Executive Chairman, Managing Director and Company Secretary | Company Secretary since 23 Nov 2016. Director since the early years of the company; appointment date not disclosed in reviewed documents | 72 | Corporate finance specialist; former corporate consultant to Daiwa Securities; executive and director roles in stockbroking. Says he has structured, raised capital for and listed over 70 companies (over A$250m raised). B.Econ, MBA, Fellow of the Australian Institute of Company Directors | MEC Resources (listed, Apr 2005–present); Grandbridge Ltd, Cortical Dynamics, Molecular Discovery Systems, Diagnostic Array Systems, Advent Energy and its subsidiaries (unlisted) |
Anthony (Tony) Huston | Non-Executive Director | Jun 2017–present | 71 | 45+ years in on- and offshore hydrocarbon engineering. Managed JFP NZ International (jack-up rig in NZ waters) in the 1990s; founded his own exploration and production company in 1996; recent focus on enhanced-recovery technology (US, Mexico, Oman, Italy, Turkmenistan) | Clean Hydrogen Technologies (investee); MEC Resources (listed) |
Charles Maling | Non-Executive Director | Appointment date not disclosed in reviewed documents | 72 | Former Communications Officer, WA Environmental Protection Authority (8 years); 14 years at the WA Department of Environment. Bachelor of Sociology and Anthropology | Grandbridge Ltd (unlisted) |
Directors' Remuneration
| Person (AUD) | Salary/fees FY2025 | Salary/fees FY2026 | Share-based (other) FY2026 | Performance rights expense FY2026 | Total FY2025 | Total FY2026 |
|---|---|---|---|---|---|---|
D Breeze | 148,000 | 148,000 | 7,450 | 475,600 | 678,109 | 631,050 |
C Maling | 25,000 | 25,000 | 0 | 0 | 27,807 | 25,000 |
A Huston | 35,000 | 25,000 | 278 | 0 | 38,609 | 25,278 |
Total | 208,000 | 198,000 | 7,728 | 475,600 | 744,525 | 681,328 |
Governance Overview
| Feature | Position |
|---|---|
Board size | 3 |
Independence | Maling is the most plausibly independent director. Huston sits on the board of investee CHT and of MEC Resources, which compromises independence under ASX Corporate Governance Principles. Breeze is executive |
Chair/CEO separation | None. Chairman, Managing Director and Company Secretary are the same person |
Committees | No separate audit, remuneration or nomination committees disclosed; functions are handled by the full board. Corporate Governance Statement is on the website |
Meetings | One formal board meeting in FY26. Business is conducted informally by telephone, with decisions by circular resolution (FY26 AR) |
Related-party intensity | High. The chairman is a director of Advent, Cortical, MDS and MEC, which are the principal recipients of BPH capital and loans |
Major Shareholders
| Holder | Shares | Approx. % of about 1.35bn shares |
|---|---|---|
D Breeze (including Grandbridge Ltd) | 69,750,805 | 5.2 |
A Huston | 9,438,070 | 0.7 |
C Maling | 7,337,428 | 0.5 |
Directors combined | 86,526,303 | 6.4 |
Competitive Landscape
Competitors by Segment
| Arena | Competitor | Type | Relative positioning |
|---|---|---|---|
East-coast gas supply (vs PEP-11) | Santos (Narrabri) | ASX large-cap | Onshore NSW gas project with approvals; vastly larger resources |
| — | Beach Energy | ASX mid-cap | Producing east-coast gas supplier |
| — | Amplitude Energy (formerly Cooper Energy) | ASX | Producing Gippsland/Otway gas |
| — | Comet Ridge | ASX small-cap | Queensland gas appraisal |
| — | LNG import terminal proponents (e.g., Squadron Energy, Port Kembla) | Private / infrastructure | Alternative NSW supply source |
| — | Bounty Oil & Gas | ASX micro-cap | PEP-11 JV partner (aligned, not competing) |
Brain / anaesthesia monitoring (vs Cortical) | Medtronic (BIS™) | Global medtech | Market-leading depth-of-anaesthesia monitor |
| — | Masimo (SedLine®) | Global medtech | EEG sedation monitoring |
| — | GE HealthCare (Entropy™) | Global medtech | Integrated monitoring |
| — | Philips and other OEM monitor makers | Global medtech | Integration targets as much as competitors |
Methane pyrolysis / turquoise hydrogen (vs CHT) | Hazer Group (ASX: HZR) | ASX small-cap | Iron-ore-catalyst methane pyrolysis with graphite co-product; most direct listed comparable |
| — | Monolith | Private (USA) | Plasma pyrolysis, carbon black |
| — | Modern Hydrogen; Ekona Power | Private | Pyrolysis start-ups |
| — | Steam methane reforming with carbon capture, and electrolysers | Incumbent / alternative | Main cost benchmark |
Peer Comparison FY2026
| Metric | BPH Energy | Bounty Oil & Gas | MEC Resources |
|---|---|---|---|
Listing | ASX | ASX | ASX |
Latest FY revenue | A$1.04m finance income (FY26) | — | — |
Revenue growth | +24.6% (FY26) | — | — |
Net margin | −975% (FY26) | — | — |
R&D intensity | 0% (investee-level only) | Not applicable | Not applicable |
PEP-11 exposure | Indirect, 35.8% of Advent's 85% | Direct 15% | Indirect, related to Advent |



